Development and validation of a machine learning-based prediction model for anemia risk in patients with primary lung cancer receiving platinum-based chemotherapy: a multicenter study
- 1Department of Oncology, Linfen Central Hospital , , ,
- 2Department of Medical Records and Statistics, Affiliated Banan Hospital of Chongqing Medical University , ,
Abstract
Background: Anemia represents a frequent and clinically burdensome complication in patients with primary lung cancer receiving platinum-based regimens, yet robust risk stratification tools that integrate multidimensional clinical data and undergo external validation remain scarce. This multicenter study sought to develop and externally validate a machine learning-based predictive model for CIA in this population.
Methods: A total of 3,434 patients with primary lung cancer were retrospectively enrolled from two geographically distinct institutions, with 3,097 assigned to the training/internal validation set (7:3 split) and 337 retained as an independent external validation set. Variables with missing rates exceeding 30% were excluded, and remaining missing data were imputed using multiple imputation by chained equations (MICE). Thirteen candidate predictors were preselected via univariate screening and least absolute shrinkage and selection operator (LASSO) regression. Nine machine learning algorithms were developed and comparatively evaluated using area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Model interpretability was achieved through SHapley Additive exPlanations (SHAP). The primary outcome was defined as hemoglobin levels < 100 g/L (CTCAE Grade ≥ 2) recorded during the first two cycles of chemotherapy.
Results: Among the nine candidate models, LightGBM achieved the highest discriminative performance, with AUCs of 0.871 (95% CI: 0.852–0.891) in the training set, 0.797 (95% CI: 0.763–0.831) in internal validation, and 0.684 (95% CI: 0.626–0.742) in the external validation set derived from Linfen Central Hospital. Calibration and decision curve analyses consistently demonstrated superior agreement and net clinical benefit for LightGBM across all three datasets. SHAP-based interpretation identified lymphocyte count, D-dimer, alanine aminotransferase, total bilirubin, sex, and albumin as the six most influential predictors, with D-dimer, female sex, and outpatient admission positively associated with anemia risk, whereas lymphocyte count, liver function indices, and albumin showed inverse associations.
Conclusions: The LightGBM-based model developed herein demonstrates acceptable and moderate predictive performance, satisfactory calibration, and potential clinical utility across geographically diverse populations, offering a preliminary risk-stratification tool for early identification of lung cancer patients at elevated anemia risk prior to chemotherapy initiation. However, given the modest external validation performance, cautious interpretation and further refinement are warranted before widespread clinical deployment.
Related
- Development and internal validation of a baseline prediction model for ≥10-point Oswestry Disability Index improvement by episode end among adults receiving outpatient physical therapy for low back pain : A retrospective cohort study
- Development and external validation of a risk prediction model for early peripheral intravenous catheter failure in outpatients and emergency department patients receiving consecutive infusion therapy.
- Development and validation of a simple clinical prediction model for post-stroke seizures in critically ill patients: a multicenter retrospective cohort study
- Machine Learning–Based Prediction of Major Postoperative Complications After Noncardiac Surgery Under General Anesthesia Using Routinely Available Electronic Health Record Data: Retrospective Multicenter Development and Validation Study
- Multimodal prediction of neoadjuvant chemotherapy response in locally advanced gastric cancer: a multicenter cohort study
BibTeX
@article{zhang2026development,
title = {{Development and validation of a machine learning-based prediction model for anemia risk in patients with primary lung cancer receiving platinum-based chemotherapy: a multicenter study}},
author = {Kaining Zhang and Xiao Li and Xiao Zhang and Xia Wang and Huijuan Zhang and Shuying Liu and Yating Gao and Jierong Yin and Xiaofei Li and Dongfeng Zhang},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1948751},
url = {https://europepmc.org/article/PMC/PMC13661483},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development and validation of a machine learning-based prediction model for anemia risk in patients with primary lung cancer receiving platinum-based chemotherapy: a multicenter study
AU - Kaining Zhang
AU - Xiao Li
AU - Xiao Zhang
AU - Xia Wang
AU - Huijuan Zhang
AU - Shuying Liu
AU - Yating Gao
AU - Jierong Yin
AU - Xiaofei Li
AU - Dongfeng Zhang
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1948751
UR - https://europepmc.org/article/PMC/PMC13661483
AB - Background: Anemia represents a frequent and clinically burdensome complication in patients with primary lung cancer receiving platinum-based regimens, yet robust risk stratification tools that integrate multidimensional clinical data and undergo external validation remain scarce. This multicenter study sought to develop and externally validate a machine learning-based predictive model for CIA in this population. Methods: A total of 3,434 patients with primary lung cancer were retrospectively enrolled from two geographically distinct institutions, with 3,097 assigned to the training/internal validation set (7:3 split) and 337 retained as an independent external validation set. Variables with missing rates exceeding 30% were excluded, and remaining missing data were imputed using multiple imputation by chained equations (MICE). Thirteen candidate predictors were preselected via univariate screening and least absolute shrinkage and selection operator (LASSO) regression. Nine machine learning algorithms were developed and comparatively evaluated using area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Model interpretability was achieved through SHapley Additive exPlanations (SHAP). The primary outcome was defined as hemoglobin levels < 100 g/L (CTCAE Grade ≥ 2) recorded during the first two cycles of chemotherapy. Results: Among the nine candidate models, LightGBM achieved the highest discriminative performance, with AUCs of 0.871 (95% CI: 0.852–0.891) in the training set, 0.797 (95% CI: 0.763–0.831) in internal validation, and 0.684 (95% CI: 0.626–0.742) in the external validation set derived from Linfen Central Hospital. Calibration and decision curve analyses consistently demonstrated superior agreement and net clinical benefit for LightGBM across all three datasets. SHAP-based interpretation identified lymphocyte count, D-dimer, alanine aminotransferase, total bilirubin, sex, and albumin as the six most influential predictors, with D-dimer, female sex, and outpatient admission positively associated with anemia risk, whereas lymphocyte count, liver function indices, and albumin showed inverse associations. Conclusions: The LightGBM-based model developed herein demonstrates acceptable and moderate predictive performance, satisfactory calibration, and potential clinical utility across geographically diverse populations, offering a preliminary risk-stratification tool for early identification of lung cancer patients at elevated anemia risk prior to chemotherapy initiation. However, given the modest external validation performance, cautious interpretation and further refinement are warranted before widespread clinical deployment.
SN - 2234-943X
ER -